Insulin therapy in AMI is associated with a 30% relative risk reduction in 1‐year mortality, as was demonstrated by Diabetes and Insulin‐Glucose infusion in Acute Myocardial Infarction (DIGAMI) trial (Malmberg et al., 1995). The gene discussed is INS; the disease is acute myocardial infarction.